RxDoctor Payments Data

Leaanna Cauthon

Family · Galesburg, ILNPI 1639764277

Payments from drug & device makers

$846in general payments, 2019–2025

Across 21 payments — averaging $40.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$236
  • Insulet Corporation$157
  • Novo Nordisk$129
  • Bayer$106
  • Integra Lifesciences Corporation$96
  • Sanofi-aventis U.S. LLC$95
  • plus $28 from 1 others

What the payments were for

  • Food & beverage$846100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$846 in reported general payments places this provider in the 70th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$69,817
Medicare patients
162
Services billed
1,152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide302$507,852
TrulicityDulaglutide154$192,646
JardianceEmpagliflozin115$165,799
MounjaroTirzepatide126$149,339
FarxigaDapagliflozin Propanediol120$114,959
Humalog Kwikpen U-200Insulin Lispro32$82,750
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt82$81,537
Tresiba Flextouch U-100Insulin Degludec80$76,168
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/755$69,119
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog79$56,851
Fiasp FlextouchInsulin Aspart (Niacinamide)42$51,532
Tresiba Flextouch U-200Insulin Degludec25$49,704
Lantus SolostarInsulin Glargine,hum.Rec.Anlog202$40,842
Gvoke Hypopen 2-PackGlucagon53$37,180
RybelsusSemaglutide23$32,210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$129$554,250380 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro$28$361,303342 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$95$18,82848 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,941 family providers in Illinois.

Other family in Galesburg

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →